Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 494 entries
View as:

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

Phase: N/A Priority: Normal
NCT ID: NCT02623699 Org: User:
Start: 01/20/16 End: 07/16/21 Due: 07/16/22

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

Phase: N/A Priority: Normal
NCT ID: NCT03385525 Org: User:
Start: 09/12/17 End: 10/13/17 Due: 10/13/18

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00168727 Org: User:
Start: 06/01/03 End: 10/31/05 Due: 10/31/06

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03672175 Org: User:
Start: 11/19/18 End: 03/17/20 Due: 03/17/21

TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World

Phase: N/A Priority: Normal
NCT ID: NCT00483847 Org: User:
Start: 09/30/06 End: 11/30/14 Due: 11/30/15

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT00424788 Org: User:
Start: 01/31/07 End: 10/31/07 Due: 10/31/08

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Phase: N/A Priority: Normal
NCT ID: NCT02283918 Org: User:
Start: 11/30/14 End: 08/31/15 Due: 08/31/16

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT04007367 Org: User:
Start: 08/06/19 End: 01/06/20 Due: 01/06/21

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05005338 Org: User:
Start: 07/28/21 End: 09/23/21 Due: 09/23/22

Adult Spinal Muscular Atrophy (SMA) China Registry

Phase: N/A Priority: Normal
NCT ID: NCT05618379 Org: User:
Start: 01/06/23 End: 06/01/28 Due: 06/01/29

MSPT Device Usability Study

Phase: N/A Priority: Normal
NCT ID: NCT02664324 Org: User:
Start: 03/31/16 End: 04/30/16 Due: 04/30/17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03945279 Org: User:
Start: 05/30/19 End: 06/21/21 Due: 06/21/22

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Phase: N/A Priority: Normal
NCT ID: NCT04655222 Org: User:
Start: 04/30/21 End: 10/15/21 Due: 10/15/22

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT05798520 Org: User:
Start: 07/25/23 End: 09/07/27 Due: 09/07/28

Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)

Phase: N/A Priority: Normal
NCT ID: NCT04317794 Org: User:
Start: 07/02/19 End: 07/01/27 Due: 07/01/28

GER-009-06-AVX Early Therapy in Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00492570 Org: User:
Start: 04/30/06 End: 12/31/08 Due: 12/31/09

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Phase: N/A Priority: Normal
NCT ID: NCT02460094 Org: User:
Start: 10/02/15 End: 10/19/16 Due: 10/19/17

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02228395 Org: User:
Start: 09/22/14 End: 11/13/14 Due: 11/13/15

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT01440101 Org: User:
Start: 11/30/10 End: 08/31/12 Due: 08/31/13

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

Phase: N/A Priority: Normal
NCT ID: NCT01485003 Org: User:
Start: 02/07/12 End: 11/26/18 Due: 11/26/19

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Phase: N/A Priority: Normal
NCT ID: NCT03091569 Org: User:
Start: 03/10/17 End: 01/27/18 Due: 01/27/19

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02477800 Org: User:
Start: 08/13/15 End: 08/08/19 Due: 08/08/20

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00420212 Org: User:
Start: 01/31/07 End: 02/28/11 Due: 02/28/12

Safety and Tolerability of Repeat Courses of IM Alefacept

Phase: N/A Priority: Normal
NCT ID: NCT00233662 Org: User:
Start: 12/01/02 End: 12/01/05 Due: 12/01/06

Clinical Disease Activity With Long Term Natalizumab Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02677077 Org: User:
Start: 12/31/15 End: 08/18/16 Due: 08/18/17